SEARCH

SEARCH BY CITATION

References

  • 1
    Samuel PD, Burland WL. Drug treatment of obesity. In: Bray GA (ed.). Obesity in Perspective. US Government printing office, Washington DC, 1974, pp. 419428. DHEW publication No. (NIH) 75–708.
  • 2
    Burland WL. A review of experience with fenfluramine. In: Bray GA (ed.). Obesity in Perspective. US Government printing office, Washington DC, 1974, pp. 429440. DHEW publication No. (NIH) 75–708.
  • 3
    Centre of Disease Control and Prevention. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine. US Department of Health and Human Services interim public health recommendation. JAMA 1997; 278: 17291731.
  • 4
    Scoville BA. Review of amphetamine-like drugs by the food and drug administration. In: Bray GA (ed.). Obesity in Perspective. US Government printing office, Washington DC, 1974, pp. 441444. DHEW publication no. (NIH) 75–708.
  • 5
    Arch JRS, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, Wilson S. Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 1984; 309: 163165.
  • 6
    Holloway BR, Howe R, Rao BS, Stribling D, Mayers RM, Briscoe MG, Jackson JM. ICI D7114: a novel selective beta adrenoceptor agonist selectively stimulates brown fat and increases whole body oxygen consumption. Br J Pharmacol 1991; 104: 97104.
  • 7
    Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes 1997; 21(Suppl. 1): S25S29.
  • 8
    Van Gaal LF, Broom JL, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 1998; 54: 125132.
  • 9
    Gelfand EV, Cannon CF. Rimonabant, a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs 2006; 15: 307315.
  • 10
    Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetic patients. Obes Res 2004; 12: 661668.
  • 11
    Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero RD, Parkes DG, Young AA. Anti-obesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes 2006; 30: 13321340.
  • 12
    Nielsen JA, Chapin DS, Johnson JL, Torgersen LK. Sertraline, a serotonin-uptake inhibitor reduces food intake and body weight in lean rats and genetically obese mice. Am J Clin Nutr 1992; 55(Suppl. 1): 185S189S.
  • 13
    Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M. Recombinant leptin for weight loss in obese and lean adults: a randomized controlled dose-escalation trial. J Am Med Assoc 1999; 282: 15681575.
  • 14
    Ettinger EMP, Littlejohn TW, Schwartz LS, Weiss SR, Mcllwain HH, Heymsfield SB, Bray GA, Robert WG, Heyman ER, Stambler N, Heshka S, Vicary C, Guler HP. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomised, dose-ranging study. J Am Med Assoc 2003; 289: 18261832.
  • 15
    Abraham R, Zed C, Mitchell T, Parr J, Wynn V. The Effect of a novel β-agonist BRL 26830A on weight and protein loss in obese patients. Int J Obes 1987; 11: 306A.
  • 16
    Fruhbeck G, Gomez-Ambrosi J. Control of body weight: a physiologic and transgenic perspective. Diabetologia 2003; 46: 143172.
  • 17
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North American Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America. A randomized controlled trial. J Am Med Assoc 2006; 295: 761765.
  • 18
    Stocker C, O’Dowd J, Morton NM, Wargent E, Sennitt MV, Hislop D, Glund S, Seckl JR, Arch JR, Cawthorne MA. Modulation of susceptibility to weight gain and insulin resistance in low birthweight rats by treatment of their mothers with leptin during pregnancy and lactation. Int J Obes 2004; 18: 129136.
  • 19
    Habeck M. A succulent cure to end obesity. Drug Discov Today 2002; 7: 280281.
  • 20
    Ritz P, Berrut G. Mitochondrial function, energy expenditure, aging and insulin resistance. Diabetes Metab 2005; 31(Spec 2): 55675573.